Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of a scalable single process for producing SARS-CoV-2 RBD monomer and dimer vaccine antigens.
Boggiano-Ayo T, Palacios-Oliva J, Lozada-Chang S, Relova-Hernandez E, Gomez-Perez J, Oliva G, Hernandez L, Bueno-Soler A, Montes de Oca D, Mora O, Machado-Santisteban R, Perez-Martinez D, Perez-Masson B, Cabrera Infante Y, Calzadilla-Rosado L, Ramirez Y, Aymed-Garcia J, Ruiz-Ramirez I, Romero Y, Gomez T, Espinosa LA, Gonzalez LJ, Cabrales A, Guirola O, de la Luz KR, Pi-Estopiñan F, Sanchez-Ramirez B, Garcia-Rivera D, Valdes-Balbin Y, Rojas G, Leon-Monzon K, Ojito-Magaz E, Hardy E. Boggiano-Ayo T, et al. Among authors: garcia rivera d. Front Bioeng Biotechnol. 2023 Nov 17;11:1287551. doi: 10.3389/fbioe.2023.1287551. eCollection 2023. Front Bioeng Biotechnol. 2023. PMID: 38050488 Free PMC article.
Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines.
Valdes-Balbin Y, Santana-Mederos D, Paquet F, Fernandez S, Climent Y, Chiodo F, Rodríguez L, Sanchez Ramirez B, Leon K, Hernandez T, Castellanos-Serra L, Garrido R, Chen GW, Garcia-Rivera D, Rivera DG, Verez-Bencomo V. Valdes-Balbin Y, et al. ACS Cent Sci. 2021 May 26;7(5):757-767. doi: 10.1021/acscentsci.1c00216. Epub 2021 Apr 19. ACS Cent Sci. 2021. PMID: 34075345 Free PMC article. Review.
SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies.
Valdes-Balbin Y, Santana-Mederos D, Quintero L, Fernández S, Rodriguez L, Sanchez Ramirez B, Perez-Nicado R, Acosta C, Méndez Y, Ricardo MG, Hernandez T, Bergado G, Pi F, Valdes A, Carmenate T, Ramirez U, Oliva R, Soubal JP, Garrido R, Cardoso F, Landys M, Gonzalez H, Farinas M, Enriquez J, Noa E, Suarez A, Fang C, Espinosa LA, Ramos Y, González LJ, Climent Y, Rojas G, Relova-Hernández E, Cabrera Infante Y, Losada SL, Boggiano T, Ojito E, León K, Chiodo F, Paquet F, Chen GW, Rivera DG, Garcia-Rivera D, Verez Bencomo V. Valdes-Balbin Y, et al. ACS Chem Biol. 2021 Jul 16;16(7):1223-1233. doi: 10.1021/acschembio.1c00272. Epub 2021 Jul 4. ACS Chem Biol. 2021. PMID: 34219448 Free article.
A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial.
Chang-Monteagudo A, Ochoa-Azze R, Climent-Ruiz Y, Macías-Abraham C, Rodríguez-Noda L, Valenzuela-Silva C, Sánchez-Ramírez B, Perez-Nicado R, Hernández-García T, Orosa-Vázquez I, Díaz-Hernández M, García-García MLÁ, Jerez-Barceló Y, Triana-Marrero Y, Ruiz-Villegas L, Rodríguez-Prieto LD, Puga-Gómez R, Guerra-Chaviano PP, Zúñiga-Rosales Y, Marcheco-Teruel B, Rodríguez-Acosta M, Noa-Romero E, Enríquez-Puertas J, Porto-González D, Fernández-Medina O, Valdés-Zayas A, Chen GW, Herrera-Martínez L, Valdés-Balbín Y, García-Rivera D, Verez-Bencomo V. Chang-Monteagudo A, et al. Lancet Reg Health Am. 2021 Dec;4:100079. doi: 10.1016/j.lana.2021.100079. Epub 2021 Sep 15. Lancet Reg Health Am. 2021. PMID: 34541571 Free PMC article.
A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity.
Pérez-Rodríguez S, de la Caridad Rodríguez-González M, Ochoa-Azze R, Climent-Ruiz Y, Alberto González-Delgado C, Paredes-Moreno B, Valenzuela-Silva C, Rodríguez-Noda L, Perez-Nicado R, González-Mugica R, Martínez-Pérez M, Sánchez-Ramírez B, Hernández-García T, Díaz-Machado A, Tamayo-Rodríguez M, Martín-Trujillo A, Rubino-Moreno J, Suárez-Batista A, Dubed-Echevarría M, Teresa Pérez-Guevara M, Amoroto-Roig M, Chappi-Estévez Y, Bergado-Báez G, Pi-Estopiñán F, Chen GW, Valdés-Balbín Y, García-Rivera D, Verez-Bencomo V. Pérez-Rodríguez S, et al. Vaccine. 2022 Mar 18;40(13):2068-2075. doi: 10.1016/j.vaccine.2022.02.029. Epub 2022 Feb 8. Vaccine. 2022. PMID: 35164986 Free PMC article. Clinical Trial.
A cell-based ELISA as surrogate of virus neutralization assay for RBD SARS-CoV-2 specific antibodies.
Pi-Estopiñan F, Pérez MT, Fraga A, Bergado G, Díaz GD, Orosa I, Díaz M, Solozábal JA, Rodríguez LM, Garcia-Rivera D, Macías C, Jerez Y, Casadesús AV, Fernández-Marrero B, Bermúdez E, Plasencia CA, Sánchez B, Hernández T. Pi-Estopiñan F, et al. Vaccine. 2022 Mar 18;40(13):1958-1967. doi: 10.1016/j.vaccine.2022.02.044. Epub 2022 Feb 15. Vaccine. 2022. PMID: 35193792 Free PMC article.
A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles.
Santana-Mederos D, Perez-Nicado R, Climent Y, Rodriguez L, Ramirez BS, Perez-Rodriguez S, Rodriguez M, Labrada C, Hernandez T, Diaz M, Orosa I, Ramirez U, Oliva R, Garrido R, Cardoso F, Landys M, Martinez R, Gonzalez H, Hernandez T, Ochoa-Azze R, Perez JL, Enriquez J, Gonzalez N, Infante Y, Espinosa LA, Ramos Y, González LJ, Valenzuela C, Casadesus AV, Fernandez B, Rojas G, Pérez-Massón B, Tundidor Y, Bermudez E, Plasencia CA, Boggiano T, Ojito E, Chiodo F, Fernandez S, Paquet F, Fang C, Chen GW, Rivera DG, Valdes-Balbin Y, Garcia-Rivera D, Verez Bencomo V. Santana-Mederos D, et al. RSC Chem Biol. 2021 Dec 8;3(2):242-249. doi: 10.1039/d1cb00200g. eCollection 2022 Feb 9. RSC Chem Biol. 2021. PMID: 35360883 Free PMC article.
Repeat-dose and local tolerance toxicity of SARS-CoV-2 FINLAY-FR-02 vaccine candidate in Sprague Dawley rats.
Oliva-Hernández R, Fariñas-Medina M, Hernández-Salazar T, Oyarzabal-Vera A, Infante-Bourzac JF, Rodríguez-Salgueiro S, Rodríguez-Noda LM, Arranguren-Masorra Y, Climent-Ruíz Y, Fernández-Castillo S, G-Rivera D, Santana-Mederos D, Sánchez-Ramírez B, García-Rivera D, Valdés-Barbín Y, Vérez-Bencomo V. Oliva-Hernández R, et al. Toxicology. 2022 Apr 15;471:153161. doi: 10.1016/j.tox.2022.153161. Epub 2022 Mar 29. Toxicology. 2022. PMID: 35364223 Free PMC article.
Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials.
Eugenia-Toledo-Romaní M, Verdecia-Sánchez L, Rodríguez-González M, Rodríguez-Noda L, Valenzuela-Silva C, Paredes-Moreno B, Sánchez-Ramírez B, Pérez-Nicado R, González-Mugica R, Hernández-García T, Bergado-Baez G, Pi-Estopiñán F, Cruz-Sui O, Fraga-Quintero A, García-Montero M, Palenzuela-Díaz A, Baró-Román G, Mendoza-Hernández I, Fernandez-Castillo S, Climent-Ruiz Y, Santana-Mederos D, Ramírez Gonzalez U, García-Vega Y, Pérez-Massón B, Guang-Wu-Chen, Boggiano-Ayo T, Ojito-Magaz E, Rivera DG, Valdés-Balbín Y, García-Rivera D, Vérez-Bencomo V; SOBERANA Research Group; Gómez-Maceo Y, Reyes-Matienzo R, Manuel Coviella-Artime J, Morffi-Cinta I, Martínez-Pérez M, Castillo-Quintana I, Garcés-Hechavarría A, Valera-Fernández R, Martínez-Bedoya D, Garrido-Arteaga R, Cardoso-SanJorge F, Quintero Moreno L, Ontivero-Pino I, Teresa Pérez-Guevara M, Morales-García M, Noa-Romero E, Orosa-Vázquez I, Díaz-Hernández M, Rojas G, Tundidor Y, García-López E, Muñoz-Morejon Y, Galano-Frutos E, Rodríguez-Alvarez J, Arteaga A, Medina Nápoles M, Espi Ávila J, Fontanies Fernández M. Eugenia-Toledo-Romaní M, et al. Among authors: garcia rivera d. Vaccine. 2022 Jul 29;40(31):4220-4230. doi: 10.1016/j.vaccine.2022.05.082. Epub 2022 Jun 6. Vaccine. 2022. PMID: 35691871 Free PMC article. Clinical Trial.
33 results